Reuters logo
4 years ago
BRIEF-Lundbeck and Otsuka expand collaboration on schizophrenia drug
March 7, 2013 / 6:12 AM / 4 years ago

BRIEF-Lundbeck and Otsuka expand collaboration on schizophrenia drug

COPENHAGEN, March 7 (Reuters) - Lundbeck A/S : * Says Otsuka and Lundbeck expand their existing collaboration * Says collaboration to include promotion of Abilify swallowable tablets, oral

solution, orally-disintegrating tablets and the intramuscular rapid

injectable in 14 European countries. * A once-monthly injectable form of Abilify, will be co-promoted by Otsuka and Lundbeck in the U.S. and will start becoming available there from March 18. * The drug was approved for use in schizophrenia by the U.S. FDA (Food and Drug Administration) on February 28.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below